Dr. David Roblin, MBBS FMedSci
Chief Operating Officer, Juvenescence
With close to a quarter of the world’s population over 60 years old, there is work to do to keep people fit and healthy. That’s our mission here.
Dr. David Roblin, MBBS FMedSci is The Chief Operating Officer at Juvenescence. He is also the CEO of the JuvRx division.
David recognizes his role at JuxRx can have a global impact on healthcare.
“With close to a quarter of the world’s population over 60 years old, there is work to do to keep people fit and healthy,” he states, “That’s our mission here.”
David is a distinguished scientist and physician who practiced medicine in London before joining Pfizer and Bayer where he led European R&D and developed medicines including ciprofloxacin, moxifloxacin, maraviroc and sildenafil. He has also experience as Board director and in the C-suite of biotech, moving his companies forward and raising money from private and public markets.
Dr. Roblin has a unique line of sight from academia to industry and patients and was the first COO and director of scientific translation at the Francis Crick Institute in London. He co-founded the Innovative Medicines Initiative, a €2Bn public private partnership in pre-competitive science with the European Union.
He is a Fellow of the Academy of Medical Sciences, the Royal College of Physicians and the Faculty of Pharmaceutical Medicine. He remains Honorary Professor of Medicine at Swansea University, and Translational Medicine at St George’s Hospital Medical School in London.
Dr. Roblin has a BS in biochemistry from University College London and an MBBS medical degree from St. George’s Hospital Medical School in London.
David’s personal fitness passion: 30-50km bikes rides through the English countryside.